The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.130.10.1155

The authors conducted an open clinical trial of high doses of parenteral haloperidol in the treatment of 40 acutely excited psychotic inpatients. Their preliminary results suggest that intramuscular haloperidol in doses up to 60 mg. a day is safe, effective, and well tolerated in the management of such patients. Adverse reactions, which were infrequent, included extrapyramidal symptoms, lethargy, and, in one patient, transient hypotension.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.